ZA926440B - Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus. - Google Patents

Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus.

Info

Publication number
ZA926440B
ZA926440B ZA926440A ZA926440A ZA926440B ZA 926440 B ZA926440 B ZA 926440B ZA 926440 A ZA926440 A ZA 926440A ZA 926440 A ZA926440 A ZA 926440A ZA 926440 B ZA926440 B ZA 926440B
Authority
ZA
South Africa
Prior art keywords
peptides
hbv
hepatitis
virus
lymphocyte responses
Prior art date
Application number
ZA926440A
Other languages
English (en)
Inventor
Francis V Chisari
Carlo Ferrari
Amalia Penna
Gabriele Missale
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of ZA926440B publication Critical patent/ZA926440B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA926440A 1991-08-26 1992-08-26 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus. ZA926440B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74954091A 1991-08-26 1991-08-26

Publications (1)

Publication Number Publication Date
ZA926440B true ZA926440B (en) 1993-06-07

Family

ID=25014174

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA926440A ZA926440B (en) 1991-08-26 1992-08-26 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus.

Country Status (19)

Country Link
EP (1) EP0534618B1 (de)
JP (3) JP3566284B2 (de)
AT (1) ATE320444T1 (de)
AU (1) AU679901B2 (de)
BG (1) BG98522A (de)
CA (1) CA2115927C (de)
CZ (1) CZ42894A3 (de)
DE (1) DE69233607T2 (de)
DK (1) DK0534618T3 (de)
ES (1) ES2262132T3 (de)
FI (1) FI940919L (de)
HU (1) HUT67529A (de)
IL (1) IL102963A0 (de)
NO (1) NO940661L (de)
NZ (2) NZ244102A (de)
OA (1) OA09889A (de)
PT (1) PT534618E (de)
WO (1) WO1993003753A1 (de)
ZA (1) ZA926440B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003777A1 (en) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
DE69820486D1 (de) * 1998-01-19 2004-01-22 Mogam Biotechnology Res Inst Y Liposomen, enthaltend peptidantigene, welche vom x-protein aus hepatitis b virus abstammen
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
GB0328753D0 (en) * 2003-12-11 2004-01-14 Royal Veterinary College The Hepatitis B vaccines
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
JP2017525681A (ja) * 2014-07-22 2017-09-07 アリオス バイオファーマ インク． パラミクソウイルスの治療方法
CN117018170A (zh) 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
EP3908591A4 (de) * 2019-01-11 2023-01-25 Agency for Science, Technology and Research Verwendung von hla-a*11:01-beschränkten hepatitis b virus (hbv)-peptiden zur identifizierung hbv-spezifischer cd8+-t-zellen
EP4458975A3 (de) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv-impfstoffe und verfahren zur behandlung von hbv

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939900A (de) * 1972-08-25 1974-04-13
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB9016727D0 (en) * 1990-07-31 1990-09-12 Clonit Spa Amino acid residue sequence of hepatitis b core antigen

Also Published As

Publication number Publication date
FI940919A0 (fi) 1994-02-25
NO940661L (no) 1994-04-19
CA2115927A1 (en) 1993-03-04
FI940919A7 (fi) 1994-04-25
FI940919L (fi) 1994-04-25
OA09889A (en) 1994-09-15
EP0534618A2 (de) 1993-03-31
DE69233607D1 (de) 2006-05-11
CA2115927C (en) 2009-04-21
WO1993003753A1 (en) 1993-03-04
DK0534618T3 (da) 2006-07-24
EP0534618B1 (de) 2006-03-15
HUT67529A (en) 1995-04-28
ATE320444T1 (de) 2006-04-15
HU9400582D0 (en) 1994-07-28
JP3566284B2 (ja) 2004-09-15
NZ270625A (en) 1996-12-20
EP0534618A3 (en) 1993-06-30
AU679901B2 (en) 1997-07-17
JPH06510050A (ja) 1994-11-10
JP3694299B2 (ja) 2005-09-14
DE69233607T2 (de) 2006-11-30
NO940661D0 (no) 1994-02-25
CZ42894A3 (en) 1995-02-15
NZ244102A (en) 1996-12-20
JP3694300B2 (ja) 2005-09-14
JP2003300999A (ja) 2003-10-21
PT534618E (pt) 2006-08-31
JP2003267997A (ja) 2003-09-25
ES2262132T3 (es) 2006-11-16
BG98522A (bg) 1995-05-31
IL102963A0 (en) 1993-01-31
AU2540892A (en) 1993-03-16

Similar Documents

Publication Publication Date Title
IL102963A0 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
EP0726758A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
EP0687182A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
EP1018344A3 (de) HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus
ATE322903T1 (de) Diätzusatz zur behandlung von malignitäten und virusinfektionen und verbesserung der immunfunktion
FR07C0073I2 (fr) Vaccin contre le papillomavirus
MX9202781A (es) Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana.
Mifune et al. Essential role of T cells in the postexposure prophylaxis of rabies in mice
RU99116029A (ru) Применение mycobacterium vaccae для регуляции по типу отрицательной обратной связи th2-активности иммунной системы
RU93053037A (ru) Вакцина против заболевания сумки птиц и способы лечения
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации
RU94038427A (ru) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
MC2306A1 (fr) Peptides bloquant les infections par le virus de l'immunodeficience humaine et methode de leur utilisation
Coutinho Hepatitis B vaccination
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.
Mikhailov et al. The influence of gamma irradiation on hepatitis B virus components and delta antigen.
JUNG Future strategies in hepatitis therapy: the immunological approach
Thomson IMMUNOLOGICAL AND PROTECTIVE RESPONSES TO A HERPES SIMPLEX VIRUS SUBUNIT VACCINE IN A LABIAL INFECTION MODEL IN MICE.
Gendon The control of viral diseases in the developing countries with the use of existing vaccines
Weibel its antibody (anti-HBs), hepatitis B core antigen and its antibody